Raymond James Financial Services Advisors, Inc. Ampio Pharmaceuticals, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$0.42 - $0.62 $425 - $628	-1,013 Reduced 1.56%	63,960 $30,000
Q4 2021 Feb 08, 2022	BUY	$0.56 - $1.71 $4,070 - $12,429	7,269 Added 12.6%	64,973 $37,000
Q3 2021 Nov 02, 2021	SELL	$1.21 - $1.8 $1,210 - $1,800	-1,000 Reduced 1.7%	57,704 $96,000
Q2 2021 Aug 11, 2021	BUY	$1.56 - $1.98 $780 - $990	500 Added 0.86%	58,704 $98,000
Q1 2021 May 14, 2021	BUY	$1.36 - $2.49 $680 - $1,245	500 Added 0.87%	58,204 $98,000
Q4 2020 Feb 12, 2021	SELL	$0.75 - $2.76 $5,991 - $22,049	-7,989 Reduced 12.16%	57,704 $92,000
Q3 2020 Nov 04, 2020	BUY	$0.61 - $1.17 $915 - $1,755	1,500 Added 2.34%	65,693 $63,000
Q2 2020 Jul 17, 2020	BUY	$0.47 - $0.72 $2,350 - $3,600	5,000 Added 8.45%	64,193 $41,000
Q1 2020 Apr 21, 2020	BUY	$0.36 - $0.74 $1,800 - $3,700	5,000 Added 9.23%	59,193 $25,000
Q3 2019 Nov 07, 2019	BUY	$0.38 - $0.52 $1,900 - $2,600	5,000 Added 10.16%	54,193 $27,000
Q2 2019 Aug 06, 2019	SELL	$0.39 - $0.7 $93 - $168	-240 Reduced 0.49%	49,193 $19,000
Q4 2018 Feb 11, 2019	SELL	$0.39 - $0.7 $5,988 - $10,748	-15,355 Reduced 23.7%	49,433 $20,000
Q3 2018 Nov 14, 2018	BUY	$0.44 - $3.02 $4,349 - $29,852	9,885 Added 18.0%	64,788 $33,000
Q2 2018 Jul 30, 2018	SELL	$1.66 - $3.82 $14,940 - $34,380	-9,000 Reduced 14.08%	54,903 $121,000
Q1 2018 Apr 16, 2018	BUY	$2.16 - $3.48 $86,190 - $138,862	39,903 Added 166.26%	63,903 $217,000
Q4 2017 Feb 09, 2018	BUY	$0.68 - $4.19 $16,320 - $100,560	24,000	24,000 $98,000

Others Institutions Holding AMPE

# of Institutions

Shares Held

96.6K

Call Options Held

Put Options Held

Ntb Financial Corp Centennial, CO

96.6K
Shares

$0
0.01% of portfolio

View Full List

About Ampio Pharmaceuticals, Inc.

Ticker AMPE
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,287,008
Description
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an...

More about AMPE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account